Results 211 to 220 of about 640,373 (307)
In hospital resource allocation conflicts between health goods and environmental goods, a relational, co-benefits frame, rather than a dualistic, competing goods frame, is key. [PDF]
Kirchhoffer DG, Pratt B.
europepmc +1 more source
Immune Checkpoint Inhibitor–Related Myositis and Associated Triad Overlap Syndrome
Objective Immune checkpoint inhibitor (ICI) myositis is a rare but a highly morbid condition, particularly with the ICI myositis triad syndrome of myositis, myocarditis, and myasthenia gravis. We report the clinical characteristics of ICI myositis and all‐cause mortality in these patients.
Selene Rubino +9 more
wiley +1 more source
Objective The American College of Rheumatology recommends HLA‐B*58:01 allele testing before the initiation of allopurinol, specifically among Asian and African American/Black patients, due to their increased risk for severe hypersensitivity reactions. However, testing rates remain low at many health care facilities.
Abimbola Fadairo‐Azinge +6 more
wiley +1 more source
Investment feasibility and optimization strategies of RFID technology in logistics field. [PDF]
Han J +6 more
europepmc +1 more source
Objective This study aimed to investigate potential moderators influencing the effects of manual therapy and exercise therapy on pain and functional outcomes in individuals with knee and/or hip osteoarthritis, using data from the MOA trial. Design This is a secondary analysis of data from the MOA trial that compared the clinical effectiveness of manual
Daniel Cury Ribeiro +2 more
wiley +1 more source
Enhancing Healthcare Access for Older Adults through Innovative Mobility Solutions Leveraging Public Assets. [PDF]
Yokota M, Nakahara S, Nishida M.
europepmc +1 more source
Objectives Systemic lupus erythematosus (SLE) is a heterogenous inflammatory condition, with widely varying global prevalence estimates. Frequency of SLE in the general population of Australia has been reported to be notably lower than contemporary estimates in countries such as the US or UK at 19‐39 per 100,000 as opposed to 65‐97 per 100,000.
Lucinda Roper +7 more
wiley +1 more source
Structural barriers to antifungal drug development. [PDF]
Galgóczy L.
europepmc +1 more source

